Neoplasms

All Conditions

Skin and Connective Tissue Diseases

Rare Diseases

Sarcoma

Liposarcoma

Histiocytoma, Malignant Fibrous

Leiomyosarcoma

Histiocytoma

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Neoplasms, Adipose Tissue

Neoplasms, Fibrous Tissue

Neoplasms, Connective Tissue

Soft Tissue Sarcoma

Undifferentiated Pleomorphic Sarcoma

All Drugs and Chemicals

Antineoplastic Agents

Antibodies

Avelumab

Immunoglobulins

Antineoplastic Agents, Immunological

Dose Escalation: Up to 18 pts with locally advanced or metastatic high-grade sarcomas Dose Expansion: 10 pts per each diagnosis - undifferentiated pleomorphic sarcoma or myxofibrosarcoma, Leiomyosarcoma, Dedifferentiated liposarcoma

DCC-3014 will be administered in pill form. Start Day 1 on first cycle and continue with dosing of DCC-3014.

DCC-3014

Start Day 1 on first cycle with further infusions of avelumab every 14 days

Sandra D'Angelo, MD

This study is being done to find the safest dose of DCC-3014 that can be given with avelumab to participants with advanced or metastatic sarcomas that will not cause serious side effects.

Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas

A Phase 1b Dose Escalation and Dose Expansion Study of a CSF1R Inhibitor (DCC-3014) Administered Concurrently With an Anti-PD-L1 Antibody (Avelumab) in Patients With Advanced High-grade Sarcoma

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Identify the maximum tolerated dose (MTD) by evaluating toxicity using NCI CTCAE (version 4.03)

Best overall response rate (CR+PR) based on RECIST v1.1

ENABLE MEDICINE

Memorial Sloan Kettering Cancer Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas	NCT04242238	Sarcoma Advanced Sarcom... High Grade Sarc... Leiomyosarcoma Undifferentiate... Myxofibrosarcom... Dedifferentiate...	DCC-3014 Avelumab	18 Years -	Memorial Sloan Kettering Cancer Center
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas	NCT04242238	Sarcoma Advanced Sarcom... High Grade Sarc... Leiomyosarcoma Undifferentiate... Myxofibrosarcom... Dedifferentiate...	DCC-3014 Avelumab	18 Years -	Memorial Sloan Kettering Cancer Center

Spots Global Cancer Trial Database for csf1r inhibitor